HRAS - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	ABR	ABR activator of RhoGEF and GTPase	NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle
Novel	ACTG1	actin gamma 1	Translocation of SLC2A4 (GLUT4) to the plasma membrane Gap junction degradation Formation of annular gap junctions Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation EPHB-mediated forward signaling EPH-ephrin mediated repulsion of cells Adherens junctions interactions Adherens junctions interactions Recycling pathway of L1 Recycling pathway of L1 VEGFA-VEGFR2 Pathway Interaction between L1 and Ankyrins Interaction between L1 and Ankyrins Cell-extracellular matrix interactions RHO GTPases activate IQGAPs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Clathrin-mediated endocytosis RHOBTB2 GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Regulation of CDH1 Function Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC)	Copper Artenimol
Novel	AFDN	afadin, adherens junction formation factor		(5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one
Novel	AGTR1	angiotensin II receptor type 1	Peptide ligand-binding receptors G alpha (q) signalling events Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Valsartan Olmesartan Losartan Candesartan cilexetil Eprosartan Telmisartan Irbesartan Forasartan Saprisartan Tasosartan CYT006-AngQb Azilsartan medoxomil Fimasartan Angiotensin II Candesartan	Renal tubular dysgenesis
Novel	ANAPC1	anaphase promoting complex subunit 1	Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation
Novel	ANKRD11	ankyrin repeat domain containing 11
Novel	ANKRD16	ankyrin repeat domain 16
Novel	ANKRD23	ankyrin repeat domain 23
Novel	ANKRD34B	ankyrin repeat domain 34B
Novel	APBB1IP	amyloid beta precursor protein binding family B member 1 interacting protein	Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants
Novel	ARAF	A-Raf proto-oncogene, serine/threonine kinase	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	ATP	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	ARFGAP1	ARF GTPase activating protein 1	XBP1(S) activates chaperone genes COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic Clathrin-mediated endocytosis
Novel	ARHGAP10	Rho GTPase activating protein 10	Regulation of PAK-2p34 activity by PS-GAP/RHG10 RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle
Novel	ARHGAP29	Rho GTPase activating protein 29	RHOA GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle
Novel	ARHGEF1	Rho guanine nucleotide exchange factor 1	NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle
Novel	ARHGEF18	Rho/Rac guanine nucleotide exchange factor 18	NRAGE signals death through JNK TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G alpha (12/13) signalling events RHOA GTPase cycle RAC1 GTPase cycle
Novel	BCL2	BCL2 apoptosis regulator	Activation of BAD and translocation to mitochondria BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Interleukin-4 and Interleukin-13 signaling The NLRP1 inflammasome Estrogen-dependent gene expression Estrogen-dependent nuclear events downstream of ESR-membrane signaling NFE2L2 regulating tumorigenic genes Regulation of MITF-M-dependent genes involved in apoptosis	Ibuprofen Paclitaxel Docetaxel Rasagiline AN-9 Paclitaxel docosahexaenoic acid Apoptone Eribulin Dexibuprofen Venetoclax Obatoclax Navitoclax Terpinen-4-ol Oleandrin	Cervical cancer Kaposi's sarcoma Chronic lymphocytic leukemia (CLL) Gastric cancer Nasopharyngeal cancer Choriocarcinoma Small cell lung cancer
Novel	BLID	BH3-like motif containing, cell death inducer
Novel	BMPR1A	bone morphogenetic protein receptor type 1A	Signaling by BMP	Dibotermin alfa	Juvenile polyposis syndrome Hereditary mixed polyposis syndrome
Novel	BRAF	B-Raf proto-oncogene, serine/threonine kinase	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer

Search Results for: HRAS